Dow Pharmaceutical Sciences

Dermatology company that specializes in the development of topical products on a proprietary basis, as well as for pharmaceutical and biotechnology companies.

Developed topical formulations and dermatology products for proprietary pipeline and pharmaceutical clients

Dow Pharmaceutical Sciences was a leading dermatology R&D organization and the premier outsourced developer of topical dermatology products for external sponsors. At the time of its acquisition, the company’s product portfolio included a newly approved topical medication and a robust pipeline of five dermatology products, three of which were in Phase II clinical development. Dow Pharma also offered a full range of product development services including formulation and regulatory consulting, formulation optimization utilizing state-of-the-art in-vitro permeation models, full analytical support, cGMP clinical manufacturing and clinical labeling. The company conducted dermatology studies at clinical sites in the United States and Europe, and was based in Petaluma, California.Developed topical formulations and dermatology products for proprietary pipeline and pharmaceutical clients

Transaction Summary

  • Having identified Dow Pharmaceuticals as the leading outsourced provider of dermatology products, Essex Woodlands made a growth equity investment in 2005 to further develop the company's internal drug pipeline and thereby complement its established services business.
  • In December 2008, Dow Pharmaceuticals was sold to Valeant Pharmaceuticals for $285 million in upfront cash. The following year Valeant bought-out the rights to future milestone obligations from Dow shareholders for an additional one-time payment of $115 million.
  • Petaluma, CA

  • Contact:
  • www.valeant.com
  • Acquisition
  • Acquired by: Valeant Pharmaceuticals International
  • Exit date: December 10, 2008
  • Logo

Related News

“Essex Woodlands are true partners. They teamed up with management to work through problems, provide constructive suggestions and were supportive throughout. Their interactions were consistently positive and definitely unique in this business.”

Bhaskar Chaudhuri

Chief Executive Officer, Dow Pharmaceutical Sciences